CVRx, Inc. - Common Stock (CVRX)
6.1100
+0.8300 (15.72%)
NASDAQ · Last Trade: Feb 20th, 9:31 PM EST
Detailed Quote
| Previous Close | 5.280 |
|---|---|
| Open | 5.260 |
| Bid | 6.000 |
| Ask | 6.420 |
| Day's Range | 5.220 - 6.485 |
| 52 Week Range | 4.299 - 14.48 |
| Volume | 951,192 |
| Market Cap | 160.76M |
| PE Ratio (TTM) | -2.995 |
| EPS (TTM) | -2.0 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 426,606 |
Chart
About CVRx, Inc. - Common Stock (CVRX)
Cvrx Inc. is a medical technology company focused on developing and commercializing innovative solutions for the treatment of cardiovascular diseases. The company specializes in advancing minimally invasive therapies that aim to improve heart function and enhance the quality of life for patients suffering from conditions such as heart failure. By leveraging cutting-edge technology and research, Cvrx Inc. is dedicated to addressing the unmet needs in the cardiovascular space and providing healthcare professionals with effective tools to manage patient care. Through its commitment to innovation, the company strives to make a meaningful impact in the field of cardiology and transform patient outcomes. Read More
News & Press Releases
Get insights into the top gainers and losers of Friday's after-hours session.chartmill.com
Via Chartmill · February 20, 2026
Law Offices of Howard G. Smith announces an investigation on behalf of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) investors concerning the Company’s possible violations of federal securities laws.
By Law Offices of Howard G. Smith · Via Business Wire · February 19, 2026
The Law Offices of Frank R. Cruz announces an investigation of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
By Law Offices of Frank R. Cruz · Via Business Wire · February 19, 2026
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) investors concerning the Company’s possible violations of the federal securities laws.
By Glancy Prongay Wolke & Rotter LLP · Via Business Wire · February 19, 2026
CVRX Inc (NASDAQ:CVRX) Reports Mixed Q4 2025 Results, Slight EPS Misschartmill.com
Via Chartmill · February 12, 2026
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · February 17, 2026

CVRx (CVRX) Q4 2025 Earnings Call Transcript
Via The Motley Fool · February 12, 2026
The law firm of Kirby McInerney LLP continues its investigation on behalf of CVRx Inc. (“CVRx” or the “Company”) (NASDAQ:CVRX) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
By Kirby McInerney LLP · Via Business Wire · February 10, 2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · February 3, 2026
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In CVRx (CVRX) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · January 30, 2026
The law firm of Kirby McInerney LLP is investigating potential claims against CVRx Inc. (“CVRx” or the “Company”) (NASDAQ:CVRX). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
By Kirby McInerney LLP · Via Business Wire · January 29, 2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · January 27, 2026
CVRx (CVRX) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 5, 2025
CVRx reported Q2 2025 revenue of $13.59M, beating estimates, but EPS missed at -$0.57. Shares dipped slightly as losses widened despite steady Barostim commercialization.
Via Chartmill · August 4, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · May 9, 2025
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · May 9, 2025
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via Chartmill · May 9, 2025
Via Benzinga · May 9, 2025